Trials / Conditions / Chronic Venous Insufficiency, CVI

Chronic Venous Insufficiency, CVI

12 registered clinical trials studyying Chronic Venous Insufficiency, CVI — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry NCT07529756	Intervene, Inc.	—
Not Yet Recruiting	Efficacy and Safety of Endovenous Ablation for Relief of Knee Pain in Elderly Patients With Lower Extremity Va NCT07239284	Chengdu University of Traditional Chinese Medicine	—
Recruiting	Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 8 NCT07233616	Chengdu University of Traditional Chinese Medicine	—
Not Yet Recruiting	Knee Pain Relief After Endovenous Treatment for Lower Limb Varicose Veins: A Prospective Observational Study NCT07163312	Chengdu University of Traditional Chinese Medicine	—
Recruiting	Reducing Skin Tone Inequities in Chronic Venous Insufficiency NCT06798766	King's College London	—
Completed	First- or Second- Class Compression Hosiery After Endovenous Laser With Sclerotherapy and Ambulatory Phlebecto NCT06913764	Moscow City Hospital named after A.K. Eramishantsev	N/A
Active Not Recruiting	Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery NCT06642051	Sonablate	N/A
Completed	Respiratory Functions, Aerobic Capacity and Quality of Life in Chronic Venous Insufficiency NCT06785805	Izmir Democracy University	—
Completed	Adding a Combined Program of Therapeutic Exercise and Self-massage to the Conventional Approach of Compression NCT06727968	University of Valencia	N/A
Terminated	Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-US) NCT04225806	Intervene, Inc.	N/A
Completed	Clinical Study to Assess the Safety and Efficacy of Mechanochemical Ablation With Flebogrif in Patients With G NCT04558957	Balton Sp.zo.o.	N/A
Completed	Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patien NCT01402921	Pierre Fabre Medicament	Phase 3